MESOTHELIOMA | 2025-11-21
Keytruda Immunotherapy for Mesothelioma in California: Pembrolizumab Treatment Guide
Accessing Checkpoint Inhibitor Therapy at UCLA, Stanford, UCSD, and City of Hope
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published · Updated
Keytruda (pembrolizumab) represents a significant advancement in mesothelioma treatment, offering new hope through immunotherapy that harnesses the body's immune system to fight cancer. As a checkpoint inhibitor, Keytruda blocks the PD-1 protein pathway that cancer cells exploit to evade immune detection, allowing immune cells to recognize and attack mesothelioma. While not effective for all patients, Keytruda combined with chemotherapy has shown improved survival in clinical trials and received
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301